Results obtained with RapiTest THC (One Step Ag-Tetrahydrocannabinol Test), RapiTest MOP (One Step Morphine Test), RapiTest MET (One Step Methamphetamine Test), and RapiTest COC (One Step Cocaine Test) were compared with the results obtained with Emit d.a.u, and with gas chromatographic-mass spectrometric (GC-MS) methods. In all, 81 urine samples taken from specimens submitted for routine analysis in the Laboratory of Pharmacology and Toxicology were analyzed. Samples were screened with Emit, reanalyzed by RapiTests, and quantitated using GC-MS methods. Both positive and negative urine samples were tested. The results obtained with RapiTests correlated well with the Emit d.a.u, and GC-MS data when operating above the cutoff concentrations specified for these methods. RapiTest MOP was found to have crossreactivity with codeine and ethylmorphine, and RapiTest MET crossreacted with amphetamine.
Introduction
Drug abuse is an increasing problem worldwide (1) . It has been recognized in prisons, hospitals, schools, and among the working population. Efficient and rapid screening methods are needed in order to detect suspected abusers quickly.
A variety of techniques, including thin-layer chromatography (TLC), gas chromatography (GC), high-performance liquid chromatography (HPLC), gas chromatography-mass spectrometry (GC-MS), and capillary dectrophoresis (CE) (2) , have been used for specimen analysis, but most of these techniques are complicated and time consuming for screening purposes. In practice, immunoassays (enzyme-multiplied immunoassay technique [Emit] , fluorescence polarization immunoassay [FPIA] , and radioimmunoassay [RIA] ) have proved to be the most efficient methods for screening purposes, but Emit, FPIA, and RIA methods all require expensive equipment, which makes them unsuitable for rapid detection of drugs in small hospitals, prisons, juvenile reformatories, and rehabilitation units.
The Morwell Diagnostics RapiTest (Zurich, Switzerland) needs no expensive equipment, no sample preparation, and no specialized personnel; only a urine sample is necessary. The RapiTest kit contains the device and the pipette that are necessary for test performance. The results of the test are ready in 10 rain.
The Morwetl Diagnostics RapiTests are based on the principle of detecting cannabinoids, morphine, methamphetamine, and cocaine by means of an immunochemical reaction. The dye conjugate complex on the test membrane and the drug content of the urine specimen compete for the antibody present on the test membrane. If the urine specimen has no drug'content, the dye conjugate binds the antibody, and a red band appears in the test window. When a sufficient amount of drug is present in the urine, the dye conjugate is unable to bind the antibody, and no band appears in the window. A positive urine specimen, therefore, prevents the red band from developing in the test window. Ferrara et al. (3) conducted an experimental and statistical comparison of nine different types of techniques, six immunochemical techniques (EIA-EMIT, EZ-SCREEN, FPIA-ADx, RIACoat-A-Count, LI-Abuscreen ONTRAK, and CBI-Triage) and three chromatographic techniques (TLC-Toxi-Lab, HPLC, and HPLC-REMEDi drug profiling system), using GC-MS as the reference technique.
The purpose of this study was to investigate ttie usefulness of the RapiTest for screening of cannabis, opiates, rnnetharnphetamine and cocaine in urine and to compare the results with those obtained by Emit d.a.u, and GC-MS.
Materials

Specimens
Urine samples for the study were obtained from specimens provided by suspected drunken drivers and abusers that were submitted for routine analysis in the Laborator~ of Pharmacology and Toxicology of the National Public Health Institute. Determinations of drugs in urine and blood sampled from drivers are centralized to the National Public Health Institute in Finland (4) . Approximately 1000 samples collected from drivers are analyzed annually.
The samples investigated were stored at 5~ before testing. In all, 81 urine samples were analyzed.
Reagents
RapiTest THC, MET, MOP, and COC were a gift from Morwell Diagnostics GmbH. Emit d.a.u, cannabinoid, amphetamine class, opiate, and cocaine metabolite assay kits were purchased from Syva (San Jose, CA). Amphetamine sulfate was purchased from Merck (Darmstadt, Germany); benzoylecgonine, 11-noro 9-carboxy-Ag-tetrahydrocannabinol, and 6-monoacetylmorphine were a gift from United Nations (Vienna, Austria); and 11-nor-9-carboxy-ag-tetrahydrocannabinol-d3 and morphined3 were purchased from Radian (Austin, TX). 4-Chioroamphetamine hydrochloride was purchased from Aldrich Chemical (Steinheim, Germany); cocaine hydrochloride was purchased from Sigma (St. Louis, MO); codeine hydrochloride, dihydrocodeine tartrate, and ethylmorphine hydrochloride were obtained from Helsinki University Pharmacy (Helsinki, Finland); methamphetamine hydrochloride was obtained from Wellcome Burroughs (Dartford, England); and pentazocine hydrochloride was obtained from Sanofi Winthrop (Guildford, England).
All reagents were analytical grade or equivalent, l~-Glucuronidase type H-3 from Helix pomatia, 100,000 units per milliliter, at pH 5.0, was purchased from Sigma; dichloromethane, dimethyl sulfoxide, hydrochloric acid, iodomethane, isooctane, methanol, potassium hydroxide, sodium acetate trihydrate, sodium carbonate, sodium hydrogen carbonate, sodium hydroxide pellets, sulphuric acid, and toluene were obtained from Merck; ethyl acetate, n-hexane, and 2-propanol were obtained from BDH Analar (Poole, England); heptafluorobutyric anhydride, 2,2,3,3,3-pentafluoro-l-propanol, and tetramethylammonium hydroxide were obtained from Fluka (Buchs, Switzerland); and pentafluoropropionic anhydride was obtained from Supelco (Bellefonte, PA).
Chem Elut CEl103 extraction columns were purchased from Varian (Harbor City, CA).
Apparatus
A Syva ETS Plus analyzer was used for Emit d.a.u, assays. An HP 5890 series II gas chromatograph-5970 series mass selective detector equipped with a capillary column split-splitless injection system was employed for quantitation. The analyses were performed on a 12-m • 0.2-ram fused-silica capillary column coated with crosslinked dimethylpolysiloxane (HP-1). Quantitation of amphetamines was also performed with an HP 5710A gas chromatograph equipped with an electron capture detector (ECD) and a 2-m OV-1 packed column.
Methods
Emit
Screening of urine samples was performed on the Syva ETS Plus analyzer using Emit d.a.u, cannabinoid, amphetamine
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Journal of Analytical Toxicology, Vol. 21, January/February 1997 class, opiate, and cocaine metabolite reagents according to the manufacturers' instructions. These assays apply a cutoff concentration of 20 ng/mL for cannabinoid and a cutoff concentration of 300 ng/mL for amphetamine, morphine, and benzoylecgonine to distinguish positive from negative samples.
RapiTests
Samples were rescreened using RapiTests. The test pouch was opened, and the test was removed. Five drops of urine were pipetted into the test sample cavity marked with an S (Figure 1 ). The results were read within 3-10 rain. Two color bands in the C and T regions indicate a negative result; one color band in the C region indicates a positive result.
Quantitation of 11-nor-9-carboxy-A9-tetrahydrocannabinol (THCCOOH) (5) Two-hundred microliters of 10M KOH and I mL of methanol were added to 1 mL of urine, and the mixture was heated at 50~ for 15 min. After cooling, the mixture was made acidic by the addition of concentrated HC1 and then extracted with 5 mL of n-hexane-ethyl acetate (7:1), 11-nor-9-carboxy-A9-tetrahydrocannabinol-d3 (THCCOOH-ds), and 0.1 pg/5 mL of n-hexane-ethyl acetate serving as the internal standard. The solvent layer was evaporated to dryness, and 70 IJL of 10% tetramethylammoniumhydroxide-dimethylsulfoxide (1:20) was added. Three minutes later, 5 laL of iodomethane was added. Five minutes later, 200 IJL of 0.1M HCl was added, and the mixture was extracted with 2 mL of isooctane. The isooctane layer was evaporated to 100 IJL, and 2 IJL was injected into the GC-MS. The column oven temperature was initially kept at 60~ for 1 min and then increased to 300~ at 30~ the final time at 300~ was 3 min. Selected ion monitoring (SIM) was used for quantitation; the ions for THCCOOH were m/z 313, 357, and 372, and those for THCCOOH-d3 were m/z 316, 360, and 375.
THCCOOH standards of 0.10, 0.05, and 0.01 lJg/mL were prepared and extracted according to the procedure applied for the samples.
Quantitation of opiates
Codeine, morphine, 6-monoacetylmorphine, ethylmorphine, and dihydrocodeine were determined by means of GC-MS in SIM mode. Urine samples were extracted after enzymatic hydrolysis using Chem Elut CEll03 extraction columns (6). Sodium acetate buffer (100 pL, pH 4.5) and 40 IlL of I~-glucuronidase were added to 2 mL urine; the mixture was then hydrolyzed in a 37~ waterbath overnight. After cooling, 0.5 mL of 0.15M sodium carbonate buffer was added, and the mixture was poured into a Chem Elut column. Three minutes later, 2 x 6 mL of dichloromethane-isopropanol (7:1) was added. Pentazocine or morphine-d3 (2 IJg/10 mL extraction solvent) was used as an internal standard.
Dichloromethane-isopropanol solutions were evaporated to dryness, and 75 IlL of pentafluoropropionic anhydride (PFPA) was added to the residue. The mixture was heated for an hour in a 60~ waterbath and then evaporated. The residue was dissolved in 100 IJL of toluene; 1 IlL was then injected into the GC-MS. Morphine, codeine, ethylmorphine, dihydrocodeine,
The GC column oven temperature program was the same as that for the quantitation of THCCOOH. The ions monitored were m/z 414 and 577 for morphine, 282 and 445 for codeine, 296 and 459 for ethylmorphine, 284 and 447 for dihydrocodeine, 414 and 473 for 6-monoacetylmorphine, 363 for pentazocine, and 417 and 580 for morphine-d3.
Quantitation of cocaine and benzoylecgonine
Cocaine and benzoylecgonine were extracted in the same way as opiates, but without hydrolysis. Pentafluoropropionic anhydride (50 pL) and 25 1JL of pentafluoropropanol were added to the extraction residue, and the mixture was heated for I h at 60~ (7, 8) . After evaporation, the residue was dissolved in 100 pL of toluene. Cocaine and benzoylecgonine standards of 1, 0.5, and 0.1 pg/mL were prepared and analyzed according to the procedure applied for the samples.
The column oven temperature program was the same as that for the quantitation of THCCOOH. The ions selected for cocaine were m/z 82 and 182, and those for benzoylecgonine were m/z 82 and 421.
Quantitation of methamphetamine and amphetamine (9)
Methamphetamine and amphetamine were quantitated using direct toluene extraction and a gas chromatograph with an ECD. One milliliter of 0.5M NaOH was added to 1 mL of urine, and the mixture was then extracted with 5 mL of toluene that contained I pg of 4-chloroamphetamine/5 mL toluene as the internal standard. After centrifugation, the organic layer was transferred into another test tube and extracted with 1 mL of 0.2M H2SO4. The organic layer was discarded, 1 mL of 0.5M NaOH was added, and the mixture was extracted with 1 mL of toluene. The toluene layer was separated, and 5 IJL of heptafluorobutyric anhydride was added. After mixing, the solution was washed with I mL of saturated NaHCO3. After centrifugation, 1 IJL of toluene layer was injected into the GC. Standards of 5, 1, and 0.5 pg/mL were prepared and extracted according to the procedure applied for the samples. The GC column oven 
Results and Discussion
Characteristics of the quantitation methods are presented in Table I of morphine, codeine, and ethylmorphine detected in 23 urine samples are listed in Table V . The results obtained with RapiTests correlated well with those of Emit d.a.u, and with GC-MS when operating above the cutoff concentrations of the methods. RapiTest THC detects Ag-tetrahydrocannabinol (THC) at the concentration of 50 ng/mL and THCCOOH at the concentration of 100 ng/mL. Other cannabinoids, including ll-OH-Aa-THC at the concentration of 370 ng/mL, 8-[3-OH-Ag-THC at the concentration of 2300 ng/mL, cannabinol at the concentration of 3400 ng/mL, and 8-~,ll-dihydmxy-Ag-THC at the concentration of 5000 ng/mL, also give positive results on RapiTest THC. For Emit d.a.u. cannabinoid, the cutoff concentration of 20 ng/mL was used. We determined with GC-MS only THCCOOH, one of the main metabolites of THC in human urine, but not other cannabinoids present in urine. Above the THCCOOH concentration of 20 ng/mL, the RapiTest THC gave a positive result. The THC-COOH concentration of 14 urine samples was between 10 and Journal of Analytical Toxicology, Vol. 21, January/February 1997 20 ng/mL. These samples were all positive with Emit d.a.u. cannabinoid, and five of them were also positive with RapiTest THC. Nine of these urine samples, however, produced a faint color band in the T region upon testing with RapiTest THC, meaning that their test results were negative; in Table II these results are given in parentheses. All GC-MS negative results were also negative with RapiTest THC and Emit d.a.u, cannabinoid. In recent years, illegal drugs have been found in 30-40% of analyzed drivers' samples in Finland (4, 10) . Cannabinoid and amphetamine are the drugs most commonly detected, whereas cocaine and methamphetarnine alone are seldom detected. Only five samples out of 81 urine samples were tested with RapiTest COC and MET.
The cutoff concentration of RapiTest COC and Emit d.a.u. cocaine metabolite is 300 ng/mL. Cocaine and benzoylecgonine were quantitated by the GC-MS method. Two samples negative with the GC-MS method were also negative upon testing with RapiTest COC and Emit d.a.u, cocaine metabolite. Two samples were positive by all three methods, but one sample found with the GC-MS method to contain 0.1 mg/L cocaine and benzoylecgonine was negative upon testing with RapiTest COC and Emit d.a.u, cocaine metabolite.
When the RapiTests were investigated, none of the samples found to be amphetamine-group positive contained metharnphetamine alone. Therefore, we tested samples which contained both rnethamphetamine and amphetamine. The RapiTest MET cutoff concentrations for methamphetamine is 500 ng/mL, that of the Emit d.a.u, amphetamine group being 300 ng/mL. One sample was negative with all of the test methods. Two samples containing both amphetamine and methamphetamine (23 and 4 mg/L and 35 and 12 nag/L, respectively) and one sample containing 5 mg/L of amphetamine were positive by all three test methods. One sample containing 1 mg/L amphetamine was positive when tested with Emit d.a.u, amphetamine group but negative with RapiTest MET.
The RapiTest MOP detects morphine in urine at the concentration of 300 ng/mL, and the cutoff concentration of Emit d.a.u, opiates is also 300 ng/mL. With GC-MS method morphine, codeine, ethylmorphine, 6-monoacetylmorphine, and dihydrocodeine were quantitated. Six out of 23 samples were negative by all three methods. Five samples contained morphine alone and were positive by RapiTest MOP and Emit d.a.u. opiate. Seven samples contained codeine and morphine; two sa.mples contained codeine; one sample contained ethylmorphine and morphine; and one sample contained morphine, codeine, and ethylmorphine. One sample was positive by RapiTest MOP and Emit d.a.u, opiate, but we were unable to find morphine, codeine, ethylrnorphine, 6-acetylrnorphine, or dihydrocodeine with the GC-MS method. The urine sample probably contained some other opiate or metabolites of opiates, which we did not test with the GC-MS method.
According to the results obtained with three different methods, RapiTest THC, COC, MET, and MOP correlated well with Emit d.a.u and GC-MS. One critical factor is the color intensity at low drug concentrations. If the color of the band is faint, it may be difficult, especially for inexperienced users, to judge if the result indicates the presence of a drug. In such cases, the test must be repeated or some other method must be used. Control samples are also necessary if the result indicates the presence of a low concentration of a drug.
Overall, the RapiTests for screening of drugs are quick, easy to perform, practical, and reliable. In the case of all immunoassays, however, positive results must be confirmed by specific analytical methods (e.g., GC-MS) in order to exclude any errors caused by interfering substances that may be present in urine.
